Literature DB >> 19671245

Quantitation of N'-nitrosonornicotine (NNN) in smokers' urine by liquid chromatography-tandem mass spectrometry.

Michael Urban1, Gerhard Scherer, Dominique Kavvadias, Heinz-Werner Hagedorn, Shixia Feng, Richard Serafin, Sunil Kapur, Raheema Muhammad, Yan Jin, Paul Mendes, Hans Roethig.   

Abstract

The tobacco-specific nitrosamine N'-nitrosonornicotine (NNN) is carcinogenic to humans (IARC Group 1). Assessing the tobacco smoke-related exposure to NNN by suitable biomarkers is of interest for risk evaluation. Recently, NNN and NNN-N-glucuronide have been quantified in urine of smokers. However, it is unknown what percentage of the absorbed dose of NNN is excreted as total NNN (sum of free and conjugated NNN) in urine of smokers. We developed a sensitive method based on liquid chromatography with tandem mass spectrometry with deuterium-labeled internal standard for the determination of total NNN in human urine. The limit of quantitation of the method was 2 pg/mL with a calibration line linear up to 256 pg/mL. In a study with 16 smokers in which the respiratory retention of NNN was measured through controlled smoking, we found that on average about 1% of the pulmonary NNN dose was excreted in 24 h urine as total NNN.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19671245     DOI: 10.1093/jat/33.5.260

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  8 in total

1.  Analysis of N'-nitrosonornicotine enantiomers in human urine by chiral stationary phase liquid chromatography-nanoelectrospray ionization-high resolution tandem mass spectrometry.

Authors:  Jing Yang; Steven G Carmella; Stephen S Hecht
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2017-01-09       Impact factor: 3.205

2.  Relationships between the Nicotine Metabolite Ratio and a Panel of Exposure and Effect Biomarkers: Findings from Two Studies of U.S. Commercial Cigarette Smokers.

Authors:  Dana M Carroll; Sharon E Murphy; Neal L Benowitz; Andrew A Strasser; Michael Kotlyar; Stephen S Hecht; Steve G Carmella; Francis J McClernon; Lauren R Pacek; Sarah S Dermody; Ryan G Vandrey; Eric C Donny; Dorothy K Hatsukami
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2020-02-12       Impact factor: 4.254

3.  Applying tobacco carcinogen and toxicant biomarkers in product regulation and cancer prevention.

Authors:  Stephen S Hecht; Jian-Min Yuan; Dorothy Hatsukami
Journal:  Chem Res Toxicol       Date:  2010-06-21       Impact factor: 3.739

4.  Quantitative analysis of 3'-hydroxynorcotinine in human urine.

Authors:  Pramod Upadhyaya; Stephen S Hecht
Journal:  Nicotine Tob Res       Date:  2014-10-16       Impact factor: 4.244

5.  It is time to regulate carcinogenic tobacco-specific nitrosamines in cigarette tobacco.

Authors:  Stephen S Hecht
Journal:  Cancer Prev Res (Phila)       Date:  2014-05-07

6.  Exposure and Metabolic Activation Biomarkers of Carcinogenic Tobacco-Specific Nitrosamines.

Authors:  Stephen S Hecht; Irina Stepanov; Steven G Carmella
Journal:  Acc Chem Res       Date:  2015-12-17       Impact factor: 22.384

7.  Assessment of the Exposure to NNN in the Plasma of Smokeless Tobacco Users.

Authors:  Nikola Pluym; Gerhard Scherer; Jeffery S Edmiston; Xiaohong C Jin; Mohamadi Sarkar; Max Scherer
Journal:  Chem Res Toxicol       Date:  2022-03-17       Impact factor: 3.973

8.  Menthol's potential effects on nicotine dependence: a tobacco industry perspective.

Authors:  Valerie B Yerger
Journal:  Tob Control       Date:  2011-05       Impact factor: 6.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.